Core Viewpoint - The company anticipates a significant turnaround in profitability, projecting a profit of approximately RMB 1,184.1 million for the six months ending June 30, 2025, compared to a loss of about RMB 142.0 million in the same period of 2024 [1][2] Group 1: Financial Performance - The expected profit increase is attributed to the successful transfer of commercialization tasks for Huadongning in China and improvements in production efficiency, leading to a higher gross margin [2] - For the six months ending June 30, 2025, the company sold approximately 1,764,000 boxes of Huadongning, generating a net sales revenue of about RMB 217.4 million, compared to 846,000 boxes and RMB 102.7 million in the same period of 2024, reflecting a sales growth of 111.8% [2] - The anticipated gross profit for the six months ending June 30, 2025, is approximately RMB 117.8 million, a significant increase from RMB 47.8 million in 2024, driven by increased sales and improved gross margin [2] Group 2: Operational Changes - The company has fully taken over the commercialization tasks for Huadongning in mainland China and has appointed a sales leader with over 20 years of experience in diabetes drug commercialization to lead its sales and marketing efforts [1] - The gross margin is expected to rise from 46.5% in 2024 to approximately 54.2% for the six months ending June 30, 2025, primarily due to enhanced production efficiency and increased output, resulting in lower unit production costs [2]
华领医药-B(02552.HK)盈喜：预期中期溢利约11.84亿元